Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

You searched for:

Slide 1 Integration of Multidisciplinary Team in Diagnosing Lynch Syndrome and Early Surveillance Sonya Inderbitzin-Fischer, Gary Monroe, Samantha Hall, Mary Adamec, Aulakh Sonikpreet Objectives • Review Lynch Syndrome mismatch repair gene variants • Discuss the integration of hereditary cancer syndrome screening recommendations into clinical practice • Discuss the …
PowerPoint Presentation Cutaneous Squamous Cell Carcinoma Case Studies Jennifer Atlas, MD Cutaneous Medical Oncology Atrium Health – Levine Cancer Institute Disclosure Information Consulting or Advisory Role: Bristol-Myers Squibb, Regeneron, Pfizer Case #1: 63 year old man with cSCC scalp • Past Medical History: Diabetes mellitus type II, …
Anthony, Fran Patient Financial Counselor, Tennessee Oncology, Nashville, TN Armstrong, Margaret MSN, M.Ed, RN, Researcher, O'Neal Comprehensive Cancer Center at UAB, Birmingham, AL Bowman, Eustacia Financial Counselor, Novant Health Cancer Institute, Charlotte, NC Chen, Shu-Fan Clinical Research Coordinator, Cedars-Sinai Medical Center, Los Angeles, CA Cousino, Pamela …
MOONSHOT FROM SAN ANTONIO 12/6/2022 THROUGH 12/10/2022 SABCS 45 TACOS 4/22/23 Disclosures/Acknowledgements I am an employed physician at Dignity Health I am have been volunteer at Casting for Recovery Thank you to Ann Partridge for permission to use her slide set from the POSITIVE trial Thank you Sudeep Gupta for use of slides Thank you Ruth O’Regan for use of slides Thanks …
TREATMENT SUMMARY Name of Patient: Oncologist: Contact Info: DIAGNOSIS Cancer Type/Location/Pathology: Ex. Poorly differentiated carcinoma of the left breast; Ki-67 of 30% Diagnosis Date: Stage: I II III IV Not applicable TREATMENT Surgery: Yes No If yes, surgical procedure/location/findings: Surgery Date: …
Alternative Payment Models and Methods Potential Impact of I-O Therapies Jennifer Hinkel, MSc Partner, McGivney Global Advisors ICLIO National Conference 9.30.16 Philadelphia, Pa. accc-iclio.org Alternative Payment Models and Methods Potential Impact of I-O Therapies Alternative Payment for Medicare Part B / Medical Benefit Drugs …
PowerPoint Presentation Collaborative Payor-Provider Partnerships Terri Salter, RN, MSNA, MBA Sr. Director, Community Cancer & Value Based Programs O’Neal Comprehensive Cancer Center at UAB Objectives •Describe UAB’s APM Experience •Define Drivers for UAB Value Based Partnerships •Review Process and Model Development •Describe Challenges and Successes to Support …
PowerPoint Presentation Hyperkalemia in the setting of newly diagnosed hepatocellular carcinoma Westergard, E.1, Zarmbinski, B.1 1Abbott Northwestern Hospital, Department of Graduate Medical Education, Minneapolis MN Clinical Presentation A 63-year-old African American male with history of alcohol abuse and hypertension presented with two days of worsening epigastric abdominal pain. Bedside …
Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) Post-ASCO Immunotherapy Highlights (Part 1): Checkpoint Inhibition and CAR-T Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West Clinic, PC Memphis, TN July 12, 2016 accc-iclio.org Objectives • To provide …
TREATMENT SUMMARY Name of Patient: Oncologist: Contact Info: DIAGNOSIS Cancer Type/Location/Pathology: Ex. Poorly differentiated carcinoma of the left breast; Ki-67 of 30% Diagnosis Date: Stage: I II III IV Not applicable TREATMENT WITH IMMUNOTHERAPY Names of Agent(s) Used Completion Date: (n/a, if ongoing) Side Effects Experienced • • …
PowerPoint Presentation Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma Seth M Maliske, MD1, Matthew J. Maurer, MS2, Carrie A. Thompson, MD3, Luis Porrata, MD3, Ivana Micallef, MD3, Rebecca L. King, MD4, Sergei Syrbu, MD, PhD5, Brian K. Link, MD1, Margarida Magalhaes Silverman, MD1, Yogesh Jethava, MBBS, MD1, David J …
PowerPoint Presentation Transition from chemotherapy (systemic) to radiotherapy (local) • CA19-9 trend may have utility in identifying distant disease in the absence of any radiologic or other indication of metastasis CA19-9 is the most important biomarker for PC1 • Normalization of CA19-9 during neoadjuvant treatment is associated with dramatically improved survival2 • Less …
PowerPoint Presentation Understanding the Undertreatment of Bile Duct Cancers: Can Big Data Save the Day? Eric H. Jensen, MD, FACS Professor and Chief, Division of Surgical Oncology John P. Delaney Chair of Clinical Surgical Oncology University of Minnesota Medical Center Minneapolis, MN 55455 jense893@umn.edu Disclosures • I am a paid consultant for Johnson and Johnson …
Upper GI/Hepatobiliary Cancers CHANDRIKHA C HANDRASEKHARAN C LINICAL A SSOCIATE PROFESSOR UNIVERSITY O F IOWA Disclosure of Conflicts of Interest Chandrikha Chandrasekharan, MD has the following financial relationship to disclose: Research funding - AstraZeneca ASCO 2022 updates in GEJ/Gastric cancers and Hepatobiliary cancers Permissions Dr. Chandrasekharan …
Assessing the prevalence and current trends in the use of cannabidiol (CBD) products in patient with active malignancy Krishna Suthar, MD1 krishna.suthar@bswhealth.org Jess Hatfield, BS2 Patricia Meyer, PharmD2 Lucas Wong, MD1 1Division of Hematology & Medical Oncology, Department of Internal Medicine Baylor Scott and White - Temple 2Texas A&M School of Medicine, …
Cancer Health Disparities; Challenges and solutions through SDoH assessment and actions • Kashyap Patel, MD, AboiM, BCMAS • Recognized by the US congress as an outstanding citizen who set the Gold Standard for decades • CEO, Carolina Blood and Cancer Care • Imm past President, Community Oncology Alliance • Imm. past Chairman, Clinical Affairs, Association of Community Cancer Centers …
Immuno-Oncology Care Transition Summary Date Completed: TREATMENT SUMMARY Name of Patient: Oncologist: Contact Info: DIAGNOSIS Cancer Type/Location/Pathology: Ex. Poorly differentiated carcinoma of the left breast; ki-67 of 30% Diagnosis Date: Stage: I II III IV Not applicable TREATMENT WITH IMMUNOTHERAPY Surgery: …
PowerPoint Presentation ASCO Direct Highlights: Colorectal and Anal Cancer South Carolina Oncology Society (SCOS) Annual Conference • Cathy Eng, MD, FACP, FASCO • David H. Johnson Chair in Surgical and Medical Oncology • Professor of Medicine, Hematology and Oncology • Co-Chair, NCI Gastrointestinal Steering Committee • Co-Director, GI Oncology • Co-Leader, Gastrointestinal …
r6uyrts Nakhle Saba, MD Tulane University Second Annual Louisiana Cancer Congress March 25, 2022 Updates in Hodgkin’s and Non- Hodgkin’s Lymphoma Disclosure of Conflicts of Interests Nakhle Saba, MD has the following financial relationships to disclose: Consultant – ADC therapeutics, BeiGene, Ibrutinib (AbbVie/PCYC/Janssen); Innocare, KyowaKirin, TG …
Bispecific Antibodies in the Lymphoma Outpatient Setting Ashley Staton, MD Bone Marrow Transplant Physician Ochsner Medical Center March 31 ,2023 Disclosures None Most Common Subtypes of Non Hodgkin Lymphoma What is a BiSpecific T Cell Engager (BiTEs) • Concept first appeared in the early 1960s • First example constructed in 1985 • BiTEs activate …